1XT.F XINTELA AB

Healthcare Biotechnology Frankfurt Exchange
0.0006 EUR
Close of Nov 9, 2026
0.0002 0.0220
Market cap
EUR 517K
P/E
-
P/B
9.95x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1XT.F undervalued?

Graham number

The Graham number of XINTELA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

XINTELA AB fundamental analysis

No fundamental analysis for XINTELA AB yet.

XINTELA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About XINTELA AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is …

Full company profile